Orgenesis CSO & Founder, Dr. Sarah Ferber, to Present at the 2013 World Stem Cell Summit on December 4
WHITE PLAINS, NY -- (Marketwired) -- 12/03/13 -- Orgenesis, Inc. (OTCQB: ORGS), a development-stage company with a novel regenerative medicine technology that converts a diabetes patient's liver cells into functioning insulin-producing cells, has been invited to present at the 2013 World Stem Cell Summit on Wednesday, December 4, 2013 at the Manchester Grand Hyatt in San Diego.
Orgenesis' Chief Science Officer and Founder, Dr. Sarah Ferber, is scheduled to speak and participate on a group panel entitled, "The Promise of Direct Reprogramming of Stem Cells," at 4:00 pm Pacific time. The panel, which is moderated by Brock Reeve of the Harvard Stem Cell Institute, will also include Marius Wernig, M.D., PhD of the Stanford University School of Medicine and Dr. Pablo Francisco Argibay from Hospital Italiano of Buenos Aires. The panelists will discuss in an open format topics in science and cell therapies, including the direct reprogramming of stem cells.
For additional information visit: www.worldstemcellsummit.com.
About Orgenesis Inc.
Orgenesis (ORGS) is a development stage company with a novel therapeutic technology that employs a molecular and cellular approach directed at converting a patient's own liver cells into functional insulin producing cells, as a treatment for diabetes. Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. For more information visit: www.orgenesis.com.
Sarah Ferber Ph.D.
Chief Science Officer & Founder
Prof. Sarah Ferber studied biochemistry at the Technion under the supervision of Professor Avram Hershko and Professor Aaron Ciechanover, winners of the Nobel Prize in Chemistry in 2004. She completed a post-doctoral fellowship at the Joslin Diabetes Center at Harvard Medical School. Ferber's breakthrough discovery suggested that humans carry their own stem-cells throughout adulthood, thus obviating the need for embryonic stem cells for generating an organ in need. Most of the research was conducted in Ferber's lab, in the Endocrine Research Lab at the Sheba Medical Center, which currently employs 11 scientists. Ferber has received TEVA, LINDNER, RUBIN and WOLFSON awards for this research. Her research work has been funded over the past 10 years by the Juvenile Diabetes Research Foundation (JDRF), the Israel Academy of Science foundation (ISF) and D-Cure, a non-profit organization that promotes and funds scientific research in Israel, aimed at finding a cure and better treatments for diabetes (together, more than $4 million US.)
About WSCS 13
The 2013 World Stem Cell Summit - December 4-6, Manchester Grand Hyatt, San Diego, California
The summit is an engine for discovery, funding and commercialization. Planned by and for the stem cell and regenerative medicine community, the Summit brings global stakeholders together to solve global challenges. The goal of the summit is to accelerate the discovery and development of lifesaving cures and therapies. The summit builds a foundation to advance cell therapies by establishing a supportive environment of regulation, legislation, financing, reimbursement and patient advocacy. http://www.worldstemcellsummit.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes which could, if successful, mean the end of diabetes as we know it; that we have an advantage over competitors with our approach to treating diabetes; Orgenesis will continue to collaborate with ATMI and other partners in the region to complete tech transfer from their R&D Operations in Tel Aviv and further automate its cell manufacturing process; and the expectation of the acceleration of Orgenesis' European clinical trial design, enrollment and overall program progression. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits Orgenesis will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to pass clinical trials so as to move on to the next phase;, our ability to retain key employees; our ability to finance development or satisfy the rigorous regulatory requirements for new medical procedures; and competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.
Company Contact: Sav DiPasquale President & Chief Executive Officer 416-509-9832 firstname.lastname@example.org Investor Relations: Chris Tyson Liolios Group, Inc. Tel (949) 574-3860 ORGS@liolios.com
Source: Orgenesis Inc.
Released December 3, 2013